Therapeutic  	Therapeutic  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
vaccines  	vaccines  	 NNS	I-NP
in  	in  	 IN	O
cervical  	cervical  	 JJ	B-NP
cancer 	cancer 	 NN	I-NP
:  	:  	 :	O
phase  	phase  	 VB	O
I  	I  	 PRP	O
study  	study  	 VBP	O
of  	of  	 IN	O
Lovaxin-C  	Lovaxin-C  	 NNP	B-NP
Producing  	Producing  	 NNP	O
effective  	effective  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
vaccines  	vaccines  	 NN	I-NP
has  	has  	 VBZ	O
proved  	proved  	 VBN	O
much  	much  	 RB	O
more  	more  	 RBR	O
difficult  	difficult  	 JJ	O
and  	and  	 CC	O
challenging  	challenging  	 VBG	O
than  	than  	 IN	O
developing  	developing  	 VBG	B-NP
cancer  	cancer  	 NN	I-NP
preventive  	preventive  	 NN	I-NP
vaccines 	vaccines 	 NNS	I-NP
.  	.  	 .	O
Despite  	Despite  	 IN	O
huge  	huge  	 JJ	O
research  	research  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
area  	area  	 NN	O
of  	of  	 IN	O
cancer  	cancer  	 NN	B-NP
immunology 	immunology 	 NN	I-NP
,  	,  	 ,	O
FDA 	FDA 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
EMEA  	EMEA  	 NNP	I-NP
have  	have  	 VBP	O
not  	not  	 RB	O
approved  	approved  	 VBD	O
any  	any  	 DT	O
type  	type  	 NN	O
of  	of  	 IN	O
cancer  	cancer  	 NN	B-NP
treatment  	treatment  	 NN	I-NP
vaccine  	vaccine  	 NN	I-NP
so  	so  	 RB	O
far 	far 	 RB	O
.  	.  	 .	O
More  	More  	 RBR	O
than  	than  	 IN	O
99 	99 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
cervical  	cervical  	 JJ	B-NP
cancers  	cancers  	 NNS	I-NP
have  	have  	 VBP	O
detectable  	detectable  	 JJ	O
amounts  	amounts  	 NNS	O
of  	of  	 IN	O
human  	human  	 JJ	B-NP
papillomavirus  	papillomavirus  	 NNS	I-NP
( 	( 	 -LRB-	O
HPV 	HPV 	 NNP	B-NP
)  	)  	 -RRB-	O
DNA 	DNA 	 NNP	B-NP
.  	.  	 .	O
Integration  	Integration  	 NN	O
of  	of  	 IN	O
high-risk  	high-risk  	 JJ	B-NP
HPV  	HPV  	 NN	I-NP
into  	into  	 IN	O
the  	the  	 DT	O
host  	host  	 NN	B-NP
cell  	cell  	 NN	I-NP
genome  	genome  	 NN	I-NP
is  	is  	 VBZ	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
continual  	continual  	 JJ	B-NP
expression  	expression  	 NN	I-NP
of  	of  	 IN	I-NP
HPV  	HPV  	 NNP	I-NP
E6  	E6  	 NNP	I-NP
and  	and  	 CC	O
E7  	E7  	 CD	B-NP
oncoproteins 	oncoproteins 	 NN	I-NP
,  	,  	 ,	O
making  	making  	 VBG	O
them  	them  	 PRP	O
excellent  	excellent  	 JJ	O
targets  	targets  	 NNS	O
for  	for  	 IN	O
developing  	developing  	 VBG	B-NP
vaccines  	vaccines  	 NNS	I-NP
which  	which  	 WDT	O
could  	could  	 MD	O
be  	be  	 VB	O
used  	used  	 VBN	O
in  	in  	 IN	O
high  	high  	 JJ	O
grade  	grade  	 NN	B-NP
precancerous  	precancerous  	 NNS	I-NP
( 	( 	 -LRB-	O
CIN 	CIN 	 NNP	B-NP
)  	)  	 -RRB-	O
lesions  	lesions  	 NNS	O
or  	or  	 CC	O
invasive  	invasive  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
or  	or  	 CC	O
in  	in  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
cancer  	cancer  	 NN	B-NP
recurrence 	recurrence 	 NN	I-NP
.  	.  	 .	O
Therapeutic  	Therapeutic  	 JJ	B-NP
cervical  	cervical  	 JJ	I-NP
cancer  	cancer  	 NN	I-NP
vaccines  	vaccines  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
extensively  	extensively  	 RB	O
studied 	studied 	 VBN	O
.  	.  	 .	O
Strategies  	Strategies  	 NNS	O
used  	used  	 VBN	O
were  	were  	 VBD	O
vaccination  	vaccination  	 VBN	O
with  	with  	 IN	O
HPV  	HPV  	 NNP	B-NP
peptides  	peptides  	 NN	I-NP
or  	or  	 CC	O
proteins 	proteins 	 NNS	O
,  	,  	 ,	O
alone  	alone  	 RB	O
or  	or  	 CC	O
in  	in  	 IN	O
pulsed  	pulsed  	 JJ	O
dendritic  	dendritic  	 JJ	B-NP
cells 	cells 	 NNS	I-NP
,  	,  	 ,	O
DNA  	DNA  	 NNP	B-NP
vaccines 	vaccines 	 NNS	I-NP
,  	,  	 ,	O
virus-like  	virus-like  	 JJ	B-NP
particles  	particles  	 NN	I-NP
or  	or  	 CC	O
viral  	viral  	 JJ	O
and  	and  	 CC	O
bacterial  	bacterial  	 JJ	B-NP
vectors 	vectors 	 NN	I-NP
.  	.  	 .	O
Lovaxin-C  	Lovaxin-C  	 NNP	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
recombinant  	recombinant  	 JJ	O
live-attenuated  	live-attenuated  	 JJ	O
Listeria  	Listeria  	 JJ	B-NP
monocytogenes  	monocytogenes  	 NNS	I-NP
( 	( 	 -LRB-	O
Lm 	Lm 	 NNP	B-NP
)  	)  	 -RRB-	O
that  	that  	 WDT	O
secretes  	secretes  	 VBZ	O
the  	the  	 DT	O
antigen  	antigen  	 JJ	B-NP
HPV-16  	HPV-16  	 CD	I-NP
E7  	E7  	 CD	I-NP
fused  	fused  	 NN	I-NP
to  	to  	 TO	O
a  	a  	 DT	O
non-hemolytic  	non-hemolytic  	 JJ	B-NP
listeriolysin  	listeriolysin  	 JJ	I-NP
O  	O  	 NNP	I-NP
protein 	protein 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
a  	a  	 DT	O
phase  	phase  	 NN	O
I  	I  	 PRP	O
study  	study  	 VBP	O
Lovaxin-C  	Lovaxin-C  	 NNP	B-NP
was  	was  	 VBD	O
administered  	administered  	 VBN	O
to  	to  	 TO	O
advanced  	advanced  	 JJ	O
cervical  	cervical  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
patients  	patients  	 NNS	I-NP
refractory  	refractory  	 VBP	O
to  	to  	 TO	O
existing  	existing  	 VBG	B-NP
therapies 	therapies 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
dose-limiting  	dose-limiting  	 JJ	O
toxicity  	toxicity  	 NN	O
was  	was  	 VBD	O
hypotension  	hypotension  	 JJ	O
and  	and  	 CC	O
flue-like  	flue-like  	 JJ	B-NP
syndrome 	syndrome 	 NN	I-NP
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
no  	no  	 DT	O
serious  	serious  	 JJ	O
adverse  	adverse  	 JJ	O
events 	events 	 NNS	O
.  	.  	 .	O
Specific  	Specific  	 JJ	B-NP
T-cell  	T-cell  	 JJ	I-NP
response  	response  	 NN	I-NP
was  	was  	 VBD	O
detected  	detected  	 VBN	O
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
clinical  	clinical  	 JJ	B-NP
response  	response  	 NN	I-NP
to  	to  	 TO	O
Lovaxin-C 	Lovaxin-C 	 JJ	B-NP
.  	.  	 .	O
Several  	Several  	 JJ	O
other  	other  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
HPV  	HPV  	 NN	I-NP
vaccines  	vaccines  	 NNS	I-NP
are  	are  	 VBP	O
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
development  	development  	 NN	I-NP
and  	and  	 CC	O
in  	in  	 IN	O
most  	most  	 JJS	O
of  	of  	 IN	O
the  	the  	 DT	O
studies  	studies  	 NNS	O
specific  	specific  	 JJ	O
immunological  	immunological  	 NN	B-NP
and  	and  	 CC	O
clinical  	clinical  	 JJ	B-NP
responses  	responses  	 NNS	I-NP
were  	were  	 VBD	O
seen 	seen 	 VBN	O
.  	.  	 .	O
Efficacious  	Efficacious  	 JJ	B-NP
therapeutic  	therapeutic  	 JJ	I-NP
vaccine  	vaccine  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
cervical  	cervical  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
should  	should  	 MD	O
be  	be  	 VB	O
expected  	expected  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
near  	near  	 JJ	O
future 	future 	 NN	O
.  	.  	 .	O
